Business Context and Reporting Period
This Form 8-K Current Report was filed by MapLight Therapeutics, Inc. on June 18, 2026. The report discloses a material change in executive leadership involving the departure of the Chief Financial Officer and the appointment of an interim replacement.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on personnel changes and does not contain financial statements or operational results.
Material Changes
- Departure of CFO: Vishwas Setia was separated as Chief Financial Officer effective June 18, 2026, following a review of a human resources violation.
- Reason for Departure: The separation was explicitly stated as unrelated to the Company's financial or operating results, internal controls, clinical programs, or financial reporting practices.
- Compensation: Mr. Setia is not entitled to severance. He received a release of claims and continued health coverage under COBRA for up to three months.
- Interim Appointment: Jonathan Gillis, previously the Chief Administrative and Accounting Officer, was appointed as interim Chief Financial Officer and interim principal financial officer effective June 18, 2026. He will also continue as principal accounting officer.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or management commentary regarding future financial performance or clinical milestones. The primary risk disclosed is the immediate leadership transition within the finance function, though management asserts this event does not impact financial reporting integrity or operations.
Investor Verification Checklist
- Verify the terms of the Separation Agreement with Mr. Setia, which is expected to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2026.
- Review the background and experience of Jonathan Gillis as detailed in the definitive proxy statement filed on April 29, 2026.
- Monitor upcoming filings for any updates on the search for a permanent Chief Financial Officer.
- Confirm that the "human resources violation" cited does not evolve into a broader compliance or governance issue in future disclosures.